Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

Invitae Corp

Start price
Target price
Perf. (%)
€3.50
21.08.22
€1.00
21.08.23
-21.28%
04.09.22

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€214.90
21.08.22
€87.00
21.08.23
-3.44%
04.09.22

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
buy
Invitae Corp

Start price
Target price
Perf. (%)
€3.32
26.08.22
-
26.08.23
-17.03%
03.09.22

Could be very worthwhile Investment >20% year
buy
Molina Healthcare

Start price
Target price
Perf. (%)
€247.40
20.10.21
€280.00
31.12.23
39.05%
01.09.22

Could be very worthwhile Investment >20% year
buy
Tandem Diabetes Care Inc

Start price
Target price
Perf. (%)
€91.50
10.08.21
-
10.08.22
-42.25%
10.08.22

buy
Global Blood Therapeutics Inc

Start price
Target price
Perf. (%)
€33.09
30.10.21
€45.00
31.12.23
94.65%
05.08.22

Could be very worthwhile Investment >20% year
buy
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€152.65
16.11.21
€200.00
31.01.25
36.59%
03.08.22

Could be worthwhile Investment >10% per year
buy
Repligen Corp.

Start price
Target price
Perf. (%)
€210.00
03.08.21
-
03.08.22
13.21%
03.08.22

buy
Repligen Corp.

Start price
Target price
Perf. (%)
€174.95
08.07.21
-
08.07.22
-2.46%
08.07.22

buy
Halozyme Therapeutics Inc.

Start price
Target price
Perf. (%)
€38.17
08.07.21
-
08.07.22
30.25%
08.07.22

buy
Catalent Inc.

Start price
Target price
Perf. (%)
€97.50
08.07.21
-
08.07.22
11.30%
08.07.22

buy
Bio-Techne Corp.

Start price
Target price
Perf. (%)
€24.00
08.07.21
-
08.07.22
-7.29%
08.07.22

buy
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€146.45
08.07.21
-
08.07.22
2.31%
08.07.22

Bluebird Bio Inc.

Start price
Target price
Perf. (%)
€9.23
09.11.21
€7.00
31.12.23
-56.18%
28.06.22

Could be very worthwhile Investment >20% year
buy
Invitae Corp

Start price
Target price
Perf. (%)
€25.10
09.06.21
€30.00
09.06.22
-89.88%
10.06.22

Could be worthwhile Investment >10% per year
buy
Bluebird Bio Inc.

Start price
Target price
Perf. (%)
€2.81
30.05.22
-
30.05.23
23.85%
08.06.22

Risky Investment
buy
Arrowhead Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€54.60
08.07.21
-
08.07.22
-37.34%
21.05.22

buy
Ensign Group Inc.

Start price
Target price
Perf. (%)
€71.50
03.05.21
€78.00
03.05.22
2.80%
04.05.22

Could be worthwhile Investment >10% per year
Teladoc Health Inc

Start price
Target price
Perf. (%)
€30.77
28.04.22
€25.00
28.04.23
19.70%
03.05.22

Significant cyclical dependencies
ROE lower than 10% per year
high free float
Little known brand
buy
Nektar Therapeutics

Start price
Target price
Perf. (%)
€4.42
19.04.22
-
19.04.23
-2.94%
02.05.22

Could be worthwhile Investment >10% per year
buy
Teladoc Health Inc

Start price
Target price
Perf. (%)
€132.55
08.07.21
€150.00
08.07.22
-76.58%
29.04.22

Future proof or reliable business model
Top 10 in its market
Innovative
Growths faster than the competition
buy
Teladoc Health Inc

Start price
Target price
Perf. (%)
€54.20
16.03.22
€65.00
16.03.23
-43.24%
28.04.22

Significant cyclical dependencies
ROE lower than 10% per year
high free float
Little known brand
buy
Teladoc Health Inc

Start price
Target price
Perf. (%)
€158.00
04.04.21
€75.00
04.04.22
-56.02%
05.04.22

Could be worthwhile Investment >10% per year
Higher EBIT margin than peer group
Good rating
ROE higher than 10% per year
buy
Agios Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€25.74
20.02.22
€30.00
20.03.22
2.76%
21.03.22

Could be worthwhile Investment >10% per year
Novocure Ltd

Start price
Target price
Perf. (%)
€59.26
09.01.22
€51.00
09.01.23
8.34%
16.03.22

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group